Answers are grounded in this paper and cite their sources.
Progressive multifocal leukoencephalopathy (PML) may develop in follicular lymphoma patients treated with bendamustine-rituximab. In this report, treatment with pembrolizumab successfully inhibited the clinical progression of PML by promoting radiologically demonstrated immune restoration inflammatory syndrome (IRIS), allowing complete clearance of the virus. These findings may further support the use of pembrolizumab in PML with special consideration for the potential occurrence of IRIS.
No takes yet. Share an insight, caveat, or question.
Dufour et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: